Zeroing in on a Biomarker Test for Parkinson's Disease
Science
Zeroing in on a Biomarker Test for Parkinson's Disease
Lundbeck is collaborating with experts at the Danish Technical University on a project that aims to facilitate early diagnosis of Parkinson's disease.
Greening Lundbeck, Greening the Grid
Our Impact
Greening Lundbeck, Greening the Grid
With construction of a new solar park now complete, Lundbeck takes a step closer to net-zero emissions.
New Analysis Finds Franklin County, Ohio Had Highest Percentage of Population Screen At-Risk for Psychotic-Like Experiences of All Large Counties in 2020 and 2021
News Releases
New Analysis Finds Franklin County, Ohio Had Highest Percentage of Population Screen At-Risk for Psychotic-Like Experiences of All Large Counties in 2020 and 2021
Lundbeck reports positive results for VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures
News Releases
Lundbeck reports positive results for VYEPTI® (eptinezumab-jjmr) from the DELIVER study in patients with migraine and prior preventive treatment failures
Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention
News Releases
Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention
Lu AF82422 represents a novel approach for potential treatment of multiple system atrophy (MSA), which currently represents a high and urgent unmet medical need.

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site are subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. 

© Copyright 2022 Lundbeck. All rights reserved.